IL-12/IL-23抑制剂治疗银屑病

[1] IL-12/IL-23 inhibitors:a promising approach to the treatment of inflammatory disorders. Wada Y. Drugs of the Future . 2008

[2] IL-12/IL-23 Inhibitors:The Advantages and Disadvantages of this Novel Approach for the Treatment of Psoriasis. Bartlett BL,Moody MN,Tyring SK. Skin Therapy Left . 2008

[3] Efficacy and safety of ustekinumab,a human interleukin-12/23 monoclonal antibody, in patients with psoriasis:76-week results from a randomised, double-blind,placebo-controlled trial (PHOENIX 1 ). Leonardi CL,Kimball AB,Papp KA,et al. The Lancet . 2008

[4] Meeting briefing. Department of Health and Human Services,Food and Drug Administration,Center for Drug Evaluation and Research,Dermatologic and Ophthalmic Drugs Advisory Committee. http://www.fda. gov/ohrms/dockets/ac/08/briefing/2008-4 361B 1-01-FDA%20.pdf . 2008

[5] Ustekinumab gains EC marketing approval.Med- wirenews. McDermid E. hhtp://medwire-news. md/60/80521/Psoriasis/Ustekinumab_gains_EC_marketing_approval. html . 2009

[6] Therapeutic effect of the potent IL-12/IL-23 inhibitor STA-5326 on experimental autoimmune uveoretinitis. Keino H,Watanabe T,Sato Y,et al. Arthritis Research and Therapy . 2008

[7] Interleukin-35:odd one out or part of the family?. Collison LW,Vignali DA. Immunological Reviews . 2008

[8] ABT-874,a fully human monoclonal anti-IL-12/IL-23 antibody for the potentialtreatment of autoimmune diseases. Ding C,Xu J,Li J. Current Opinion in Investigational Drugs . 2008

[9] Dendritic cells:a conductor of T cell differentiation. Kadowaki N. Allergology International . 2007

[10] Modulation of CLA, IL-12R, CD40L, and IL-2Rα expression and inhibition of IL-12- and IL-23-induced cytokine secretion by CNTO 1275[J] . Manjula Reddy,Cuc Davis,Jackson Wong,Paul Marsters,Charles Pendley,Uma Prabhakar. &nbspCellular Immunology . 2007 (1)

[1] IL-12/IL-23 inhibitors:a promising approach to the treatment of inflammatory disorders. Wada Y. Drugs of the Future . 2008

[2] IL-12/IL-23 Inhibitors:The Advantages and Disadvantages of this Novel Approach for the Treatment of Psoriasis. Bartlett BL,Moody MN,Tyring SK. Skin Therapy Left . 2008

[3] Efficacy and safety of ustekinumab,a human interleukin-12/23 monoclonal antibody, in patients with psoriasis:76-week results from a randomised, double-blind,placebo-controlled trial (PHOENIX 1 ). Leonardi CL,Kimball AB,Papp KA,et al. The Lancet . 2008

[4] Meeting briefing. Department of Health and Human Services,Food and Drug Administration,Center for Drug Evaluation and Research,Dermatologic and Ophthalmic Drugs Advisory Committee. http://www.fda. gov/ohrms/dockets/ac/08/briefing/2008-4 361B 1-01-FDA%20.pdf . 2008

[5] Ustekinumab gains EC marketing approval.Med- wirenews. McDermid E. hhtp://medwire-news. md/60/80521/Psoriasis/Ustekinumab_gains_EC_marketing_approval. html . 2009

[6] Therapeutic effect of the potent IL-12/IL-23 inhibitor STA-5326 on experimental autoimmune uveoretinitis. Keino H,Watanabe T,Sato Y,et al. Arthritis Research and Therapy . 2008

[7] Interleukin-35:odd one out or part of the family?. Collison LW,Vignali DA. Immunological Reviews . 2008

[8] ABT-874,a fully human monoclonal anti-IL-12/IL-23 antibody for the potentialtreatment of autoimmune diseases. Ding C,Xu J,Li J. Current Opinion in Investigational Drugs . 2008

[9] Dendritic cells:a conductor of T cell differentiation. Kadowaki N. Allergology International . 2007

[10] Modulation of CLA, IL-12R, CD40L, and IL-2Rα expression and inhibition of IL-12- and IL-23-induced cytokine secretion by CNTO 1275[J] . Manjula Reddy,Cuc Davis,Jackson Wong,Paul Marsters,Charles Pendley,Uma Prabhakar. &nbspCellular Immunology . 2007 (1)